Dr. Kris on the RELAY Trial in EGFR+ NSCLC
August 30th 2019Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.
Read More
Dr. Kris on Predicting Benefit With Osimertinib in EGFR+ NSCLC
June 13th 2019Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).
Read More
Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC
September 28th 2018Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.
Read More
Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer
January 4th 2017Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.
Read More
Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC
June 18th 2016Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).
Read More